KCT0002497
Completed
未知
Ozurdex Treatment for macular edema associated with retinitis pigmentosa
ConditionsDiseases of the eye and adnexa
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the eye and adnexa
- Sponsor
- Seoul National University Hospital
- Enrollment
- 17
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who are at least 18 years of age and had bilateral CME associated with RP are prospectively recruited. Diagnosis of RP was based on typical funduscopic finding of bilateral retinal degeneration, visual field constriction and/or ring scotoma, and markedly reduced rod response on standard electroretinography. To be included, RP patients are required to have macular cystic change as shown by spectral domain optical coherence tomography (OCT) with central subfield macular thickness (CSMT) of \> 250 µm in both eyes.
Exclusion Criteria
- •Key exclusion criteria are as follows: (1\) advanced RP with foveal atrophic change or visual acuity of hand motion or less; (2\) aphakia or pseudophakic eyes with zonule dehiscence or defective posterior capsule; (3\) history of glaucoma or IOP elevation in response to steroid treatment in either eye; (4\) history of vitrectomy; (5\) diabetic retinopathy in either eye; (6\) any active intraocular or periocular infection in either eye; (7\) history of intravitreal or periocular steroids within 12 months; (8\) history of intraocular surgery within 6 months; (9\) any uncontrolled systemic disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Ozurdex for Macular Edema Post Membrane PeelingEpiretinal MembraneCellophane MaculopathyMacular EdemaRetinal EdemaNCT01273727Retina Specialists, PC35
Completed
Not Applicable
Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass SyndromeMacular EdemaVisual AcuityNCT01945892Ludwig-Maximilians - University of Munich23
Completed
Not Applicable
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX StudyDiabetic Macular OedemaNCT02731911Allergan202
Active, not recruiting
Phase 1
sing an anti inflammatory eye implant (Ozurdex) to help improve surgical outcomes in patients with scar tissue (PVR) on the retinaProliferative VitreoretinopathyMedDRA version: 14.0 Level: PT Classification code 10038934 Term: Retinopathy proliferative System Organ Class: 10015919 - Eye disordersTherapeutic area: Body processes [G] - Ocular Physiological Phenomena [G14]EUCTR2011-004498-96-GBMoorfields Eye Hospital140
Completed
Not Applicable
Anatomic Outcomes Following Ozurdex InjectionsRetinal Vein OcclusionsNCT01282411Barnes Retina Institute10